Boehringer Mannheim gets bedside myocardial infarction (MI) test go-ahead
This article was originally published in Clinica
Executive Summary
The US FDA has cleared Boehringer Mannheim's disposable bedside heart attack test, Cardiac T Rapid. Canada-based Spectral Diagnostics was the first to launch a bedside MI test, following US approval of its CK-MB/myoglobin panel in March (see Clinica No 644, p 18), but the Boehringer kit is the first to use cardiac-specific troponin antibodies.